{"id":"NCT00294671","sponsor":"Boston University","briefTitle":"The Effect of Diflunisal on Familial Amyloidosis","officialTitle":"The Effect of Diflunisal on Familial Amyloidosis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-02","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2006-02-22","resultsPosted":"2017-03-17","lastUpdate":"2017-03-17"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Familial Amyloid Polyneuropathy","Familial Amyloidosis"],"interventions":[{"type":"DRUG","name":"diflunisal","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Diflunisal","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy.\n\nFunding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS)","primaryOutcome":{"measure":"Neurologic Impairment Score + 7 (NIS+7)","timeFrame":"Baseline, 1 and 2 years","effectByArm":[{"arm":"Diflunisal","deltaMin":8.2,"sd":null},{"arm":"Placebo","deltaMin":26.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.02"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":8,"countries":["United States","Italy","Japan","Sweden","United Kingdom"]},"refs":{"pmids":["24368466"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":64},"commonTop":["Infections","GI disorders","Nervous system disorders","Musculoskeletal and connective tissue disorders","General disorders"]}}